Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food-effect bioavailability of gemigliptin + dapagliflozin + metformin SR in healthy volunteers
TCTR20260224004Phase 1Not yet recruiting
- Sponsor
- International Bio Service
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of gemigliptin, dapagliflozin and metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by International Bio Service. Primary endpoint: Primary pharmacokinetic parameters under fasting vs fed conditions. Planned start May 2026; status: not yet recruiting.
02
Drugs
gemigliptindapagliflozinmetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on TCTR20260224004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260224004.